All signs are pointing in the right direction for SpermVital. In 2016 the company secured deals with three new breeding companies, while increasing their turn-over by 44% compared to 2015. The company was valuated by DHT Corporate Services to 238 mNOK – more than a doubling since the last valuation in 2011.
According to CEO Nils Chr. Steig, this positive development can be attributed to a targeted market effort: ‘We see that the SpermVital proprietary technology receives a lot of positive attention, however – this is a conservative industry that is accustomed to making decisions based on solid evidence and quality-assured information’. He also adds that in the past five years, SpermVital has grown significantly and that today the company is lucky to have 20 highly competent and dedicated employees.